Technetium tc-99m sulfur colloid kit - Generic Drug Details

What are the generic sources for technetium tc-99m sulfur colloid kit and what is the scope of patent protection?

Technetium tc-99m sulfur colloid kit is the generic ingredient in five branded drugs marketed by Sun Pharm Inds Inc, Mallinckrodt, Ge Healthcare, Jubilant, and Bracco, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

Two suppliers are listed for this compound.

Summary for technetium tc-99m sulfur colloid kit

US Patents:	0
Tradenames:	5
Applicants:	5
NDAs:	5
Finished Product Suppliers / Packagers:	2
Clinical Trials:	20
DailyMed Link:	technetium tc-99m sulfur colloid kit at DailyMed

Recent Clinical Trials for technetium tc-99m sulfur colloid kit

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ohio State University Comprehensive Cancer Center	PHASE2
OnLume Inc.	Early Phase 1
National Cancer Institute (NCI)	Early Phase 1

See all technetium tc-99m sulfur colloid kit clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for technetium tc-99m sulfur colloid kit

D10AB	Preparations containing sulfur
D10A	ANTI-ACNE PREPARATIONS FOR TOPICAL USE
D10	ANTI-ACNE PREPARATIONS
D	Dermatologicals

US Patents and Regulatory Information for technetium tc-99m sulfur colloid kit

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm Inds Inc	AN-SULFUR COLLOID	technetium tc-99m sulfur colloid kit	SOLUTION;INJECTION, ORAL	017858-001	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes
Jubilant	TECHNETIUM TC-99M SULFUR COLLOID KIT	technetium tc-99m sulfur colloid kit	SOLUTION;INJECTION, ORAL	213516-001	Nov 9, 2023	AP	RX	No	No
Ge Healthcare	TECHNETIUM TC 99M TSC	technetium tc-99m sulfur colloid kit	SOLUTION;INJECTION, ORAL	017784-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Bracco	TESULOID	technetium tc-99m sulfur colloid kit	SOLUTION;INJECTION, ORAL	016923-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Mallinckrodt	TECHNECOLL	technetium tc-99m sulfur colloid kit	SOLUTION;INJECTION, ORAL	017059-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Technetium Tc-99m Sulfur Colloid Kit Market Dynamics and Financial Trajectory

Last updated: July 31, 2026

Technetium Tc-99m sulfur colloid is a mature nuclear-medicine diagnostic product with stable clinical demand, limited pricing power, and low conventional patent risk. Its financial performance is driven less by molecular innovation than by radiopharmacy utilization, technetium-99m availability, hospital imaging volumes, manufacturing reliability, and reimbursement. Public companies generally do not report revenue for sulfur colloid kits separately, so product-level sales and margins cannot be isolated from broader nuclear-medicine portfolios.

What is the Technetium Tc-99m sulfur colloid kit used for?

The kit is a nonradioactive reagent that is combined with sodium pertechnetate Tc-99m to produce Technetium Tc-99m sulfur colloid injection. The finished radiopharmaceutical is used for diagnostic imaging and localization procedures.

Clinical use	Commercial relevance
Liver and spleen imaging	Established but declining relative to ultrasound, CT and MRI in some indications
Lymphatic mapping and sentinel-node localization	Important surgical and oncology use
Bone-marrow imaging	Specialized, lower-volume application
Gastric emptying studies	Alternative nuclear-medicine application
Peritoneovenous shunt evaluation	Limited, procedure-dependent use

The product is administered intravenously, subcutaneously, orally or through other approved routes depending on the indication and product labeling. Particle size, preparation conditions and administered activity affect biodistribution and clinical performance. FDA labeling identifies sulfur colloid as a radiopharmaceutical prepared from a kit using Tc-99m pertechnetate.[1]

The radiolabeled product has a physical half-life of approximately six hours. Hospitals and nuclear pharmacies therefore purchase, prepare and administer it within a short operating window. This limits conventional inventory accumulation and makes reliable daily distribution more important than long-term stockholding.[1]

How does the Technetium Tc-99m sulfur colloid market make money?

Revenue is generated through a radiopharmaceutical supply chain rather than through a conventional prescription-drug channel.

Economic model

A typical transaction includes:

1. A healthcare provider or nuclear pharmacy purchases the sulfur colloid reagent kit.
2. The kit is reconstituted with Tc-99m supplied by a generator or centralized radiopharmacy.
3. The prepared dose is dispensed to a hospital, imaging center or surgical department.
4. The provider bills for the diagnostic procedure, radiopharmaceutical and associated technical services under applicable reimbursement rules.

The kit itself is only one component of the total procedure economics. Tc-99m generator costs, radiopharmacy labor, quality control, delivery logistics and reimbursement can exceed the value of the reagent kit in the overall transaction.

Revenue visibility

No major supplier publicly discloses a standalone global revenue line for Technetium Tc-99m sulfur colloid kits. Companies report broader segments that combine radiopharmaceuticals, diagnostic imaging agents, contract manufacturing and nuclear-medicine services. As a result, market-size estimates based on total nuclear-medicine revenue should not be treated as sulfur colloid sales.

The product is best characterized as a mature, low-growth specialty pharmaceutical with recurring procedural demand. Its financial profile is likely to include:

• Stable unit demand in established nuclear-medicine centers.
• Low average selling price relative to oncology drugs and biologics.
• High sensitivity to production interruptions.
• Local or regional supply concentration.
• Limited opportunity for premium pricing without a documented shortage or service advantage.
• Margin dependence on manufacturing scale, batch utilization and delivery density.

What are the main market drivers for Technetium Tc-99m sulfur colloid?

Tc-99m supply and reactor capacity

Technetium-99m is produced from molybdenum-99, which is manufactured primarily through nuclear-reactor systems and then distributed through Tc-99m generators or radiopharmacy networks. The global supply chain has historically faced reactor outages, processing interruptions and transport constraints.[2][3]

A sulfur colloid supplier can have adequate kit manufacturing capacity while still facing commercial disruption if customers cannot obtain Tc-99m pertechnetate. This creates a structural distinction from ordinary injectable drugs: demand may remain intact while shipments or procedures are delayed by isotope availability.

The United States has sought to reduce dependence on foreign reactor supply through domestic Mo-99 production initiatives and non-uranium-based production technologies. These policies support long-term supply resilience but do not eliminate short-term logistics risk.[4]

Surgical oncology and sentinel lymph-node procedures

Lymphatic mapping is an important demand center. Sulfur colloid can be injected near a tumor or surgical site to identify draining lymphatic channels and sentinel nodes. Breast cancer and melanoma procedures have historically supported this use, while broader adoption depends on institutional protocols, surgeon preference and availability of alternative mapping agents.

Demand is influenced by:

• Cancer incidence and surgical volumes.
• Use of sentinel-node biopsy.
• Hospital operating-room schedules.
• Availability of nuclear-medicine personnel.
• Competition from blue dyes and other lymphatic mapping approaches.

Nuclear-medicine utilization

General nuclear-medicine procedure volumes affect sulfur colloid demand, especially for liver, spleen, marrow and gastric-emptying studies. The product competes indirectly with CT, MRI, ultrasound and other diagnostic methods. In some applications, newer imaging modalities have reduced reliance on older radiocolloid studies, while surgical mapping has preserved a more specialized demand base.

How does Technetium Tc-99m sulfur colloid compare with competing products?

Product or technology	Primary use	Competitive relationship
Tc-99m sulfur colloid	Liver, spleen, lymphatic mapping, marrow and gastric studies	Core direct comparator
Tc-99m nanocolloid products	Lymphatic mapping and selected imaging	May compete where approved and commercially available
Tc-99m human serum albumin	Blood-pool and related imaging	Adjacent Tc-99m product, not a full substitute
Blue dyes	Sentinel-node mapping	Procedure-level alternative, often used with or instead of radiocolloid
CT, MRI and ultrasound	Anatomical or functional diagnosis	Substitute in selected non-surgical indications
PET radiopharmaceuticals	Oncology and advanced diagnostic imaging	Higher-cost technology with different clinical positioning

The strongest competitive protection for sulfur colloid is operational familiarity. Hospitals that have established protocols, trained staff and validated quality-control procedures may have limited incentive to switch products unless a competitor offers lower cost, better supply reliability or a clinically meaningful formulation advantage.

What patents protect Technetium Tc-99m sulfur colloid kits?

The core sulfur colloid formulation is based on an old, well-established radiopharmaceutical technology. The commercial product is unlikely to have meaningful remaining composition-of-matter patent protection. Any historical patents covering preparation methods, particle characteristics or kit components would generally be expected to have expired after the statutory patent term.

Formulation patents

Potentially relevant intellectual-property categories include:

• Sulfur colloid particle-size control.
• Kit-component stability.
• Reconstitution procedures.
• Sterility and packaging systems.
• Automated radiopharmacy preparation.
• Specific lymphatic-mapping formulations.

These rights may affect individual products or manufacturing processes, but they do not create a broad exclusionary franchise comparable to a modern small-molecule or biologic patent estate.

Method-of-use patents

The principal uses of Tc-99m sulfur colloid, including liver and spleen imaging and lymphatic mapping, are established clinical applications. Broad method-of-use patents covering these procedures would generally be old or vulnerable to expiration. Current commercial differentiation is more likely to arise from regulatory approvals, manufacturing controls, distribution capacity and institutional contracts.

Geographic coverage

Patent risk is likely low in the United States, Europe and other mature markets because of the age of the technology. Regulatory and manufacturing requirements remain jurisdiction-specific. A supplier may still need separate approvals for:

• The kit formulation.
• The radiolabeled finished product.
• Manufacturing and quality-control sites.
• Nuclear-material handling.
• Importation, transport and distribution.

Patent expiry does not eliminate these regulatory barriers.

What is the FDA regulatory and Orange Book status?

The product is regulated as a prescription radiopharmaceutical kit. FDA-approved labeling identifies the kit, its preparation requirements, approved routes and clinical indications.[1]

FDA exclusivity

Technetium Tc-99m sulfur colloid is a mature product. No meaningful remaining new chemical entity exclusivity should be expected. Any applicable regulatory exclusivity would depend on the specific approved application, supplement or pediatric designation rather than on the underlying sulfur colloid technology.

Orange Book listings

The Orange Book is most consequential for conventional prescription drugs subject to abbreviated new drug application competition. For an established radiopharmaceutical kit, the commercial barriers are often more practical than patent-driven. Relevant considerations include:

• Whether the specific reference product has current Orange Book patent listings.
• Whether a competing applicant can rely on an ANDA, 505(b)(2) application or another pathway.
• Whether the proposed product must demonstrate equivalent radiochemical performance.
• Whether labeling, particle size and preparation instructions are sufficiently comparable.

An applicant may face regulatory complexity even where patent barriers are weak. Radiopharmaceutical quality, sterility, radionuclidic purity, radiochemical purity and in-use stability require product-specific validation.

When does Technetium Tc-99m sulfur colloid lose exclusivity?

The underlying technology has already passed the period associated with meaningful innovator exclusivity. Market entry is therefore controlled by product approvals, manufacturing capability and supply economics rather than by a single future loss-of-exclusivity date.

Exclusivity category	Current commercial implication
Composition-of-matter patent	Not a meaningful barrier for this mature technology
New chemical entity exclusivity	No practical relevance
Formulation patent	Potentially relevant only for a specific modern formulation
Method-of-use patent	Limited relevance for established indications
Regulatory exclusivity	Product- and application-specific
Manufacturing know-how	More important than core patent rights
Distribution access	Major barrier because of short half-life and isotope dependence

Which companies compete in the sulfur colloid kit market?

Competition is concentrated among specialized radiopharmaceutical and nuclear-medicine suppliers. Relevant market participants have included Mallinckrodt and other regional or specialized radiopharmaceutical manufacturers, depending on country and product availability.

The competitive landscape changes through:

• Product discontinuations.
• Manufacturing-site transfers.
• Supply agreements.
• Hospital tenders.
• Nuclear-pharmacy consolidation.
• Changes in Tc-99m generator supply.
• Regulatory approval of alternative radiocolloids.

Company-level market share cannot be determined reliably from public filings because sulfur colloid sales are generally embedded in larger diagnostic or radiopharmaceutical categories.

What generic entry risks exist?

Generic or follow-on entry risk is structurally higher than for protected specialty drugs, but successful entry still requires specialized capabilities.

Main entry barriers

• Access to pharmaceutical-grade manufacturing.
• Sterile kit production.
• Radiochemical validation.
• Batch-release testing.
• Compliance with FDA current good manufacturing practice requirements.
• Reliable Tc-99m supply for finished-product testing and commercial preparation.
• Short-notice distribution to nuclear pharmacies.
• Hospital and radiology-department contracting.
• Pharmacovigilance and radiopharmaceutical quality systems.

A new entrant could gain share through lower pricing, supply continuity or preferred contracting. Price erosion is likely to be gradual rather than immediate because the kit represents only part of the total procedure cost and hospitals may prioritize supply reliability.

Paragraph IV challenges and litigation

Paragraph IV litigation risk is likely limited for the underlying sulfur colloid technology. A challenge would be more relevant if a current reference product had unexpired listed patents covering a specific formulation, kit configuration or preparation method. The principal commercial risk is therefore regulatory approval and market execution, not a high-value patent dispute.

No broad, high-profile patent litigation pattern comparable to branded oncology drugs or biologics defines this market.

How strong is the patent estate for Technetium Tc-99m sulfur colloid?

The patent estate is weak as a basis for long-term pricing power. Product defensibility rests on four operational assets:

1. Approved manufacturing capability.
2. Consistent radiochemical and sterile quality.
3. Reliable Tc-99m-linked distribution.
4. Established relationships with nuclear pharmacies and hospitals.

This is a supply-chain franchise, not a conventional patent franchise. Manufacturing know-how can delay entry, but it is less durable than enforceable exclusivity and can be replicated by specialized radiopharmaceutical companies.

What financial trajectory should investors expect?

The likely financial trajectory is mature and defensively stable rather than high-growth.

Base-case outlook

• Low single-digit demand growth or flat volume in established markets.
• Periodic revenue spikes during competitor shortages.
• Gross-margin volatility tied to batch scale, labor and distribution.
• Limited price expansion.
• Increasing importance of hospital contracts and radiopharmacy networks.
• Potential demand support from surgical oncology and lymphatic mapping.

Upside factors

• Growth in sentinel-node procedures.
• Improved Tc-99m availability.
• Supplier consolidation.
• Competitor manufacturing failures.
• Expansion of nuclear-medicine capacity in emerging markets.
• New validated applications using the same kit platform.

Downside factors

• Substitution by CT, MRI, ultrasound or PET.
• Declining use of older liver and spleen imaging protocols.
• Tc-99m supply disruptions.
• Reimbursement pressure.
• Product recalls or manufacturing interruptions.
• Hospital consolidation and tender-based price reductions.
• Loss of a major nuclear-pharmacy customer.

Revenue exposure

For diversified suppliers, sulfur colloid is unlikely to represent a material share of total corporate revenue. Its financial value is more likely to come from portfolio breadth, customer retention and contribution margin than from absolute sales scale.

What licensing and settlement agreements affect the market?

Publicly visible licensing and patent-settlement activity is not a major defining feature of this product category. Commercial agreements are more likely to involve:

• Contract manufacturing.
• Distribution through nuclear pharmacies.
• Generator or isotope supply.
• Hospital purchasing contracts.
• Regional regulatory rights.
• Manufacturing-site technology transfers.

These arrangements can materially affect availability without producing a public patent settlement. A supplier with a strong distribution network may outperform a lower-cost entrant because the product must reach the customer within a narrow radiopharmaceutical operating window.

Key Takeaways

• Technetium Tc-99m sulfur colloid is a mature diagnostic radiopharmaceutical kit.
• Its major uses are liver and spleen imaging, lymphatic mapping, bone-marrow imaging and gastric studies.
• Core patent protection is expected to be weak or expired because the technology is longstanding.
• FDA exclusivity and Orange Book issues are less important than regulatory approval, sterile manufacturing and isotope logistics.
• Tc-99m availability is a central market risk.
• Product-level revenue is not separately disclosed by major suppliers.
• Financial performance is likely stable but low growth, with episodic upside during shortages.
• Generic entry is feasible but requires specialized radiopharmaceutical manufacturing and reliable nuclear-pharmacy distribution.
• The strongest commercial moat is operational execution rather than patent exclusivity.

FAQs

Is Technetium Tc-99m sulfur colloid a generic drug?

It is a mature radiopharmaceutical kit with potential for multiple approved suppliers. Whether a specific product is classified as an ANDA generic, a 505(b)(2) product or another approved presentation depends on its FDA application and formulation.

Does sulfur colloid contain radioactive technetium when sold?

The kit generally contains the nonradioactive sulfur colloid components. Tc-99m sodium pertechnetate is added during preparation before administration.[1]

How long does Technetium Tc-99m sulfur colloid remain usable?

Usability is limited by the six-hour physical half-life of Tc-99m and by product-specific labeling for preparation, storage and expiration after reconstitution.[1]

Is sulfur colloid used for sentinel lymph-node biopsy?

Yes. Lymphatic mapping and sentinel-node localization are important clinical uses, particularly in surgical oncology.

What is the biggest commercial risk for sulfur colloid suppliers?

The primary risk is supply disruption involving Tc-99m availability, manufacturing, radiopharmacy operations or time-sensitive distribution. Patent expiry is a secondary concern.

References

1. U.S. Food and Drug Administration. (n.d.). Technetium Tc 99m sulfur colloid injection: Prescribing information. FDA Drugs@FDA and product labeling database. https://www.accessdata.fda.gov/scripts/cder/daf/

2. International Atomic Energy Agency. (n.d.). Molybdenum-99/technetium-99m supply. IAEA. https://www.iaea.org/topics/molybdenum-99-technetium-99m

3. National Academies of Sciences, Engineering, and Medicine. (2009). Medical isotope production without enriched uranium. National Academies Press. https://doi.org/10.17226/12569

4. U.S. Department of Energy, National Nuclear Security Administration. (n.d.). Molybdenum-99 production and supply. NNSA. https://www.energy.gov/nnsa/mission/defense-nuclear-nonproliferation/molybdenum-99-program.